Adjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Endocrine Therapy Plus Ribociclib Versus Chemotherapy in Intermediate Risk, HR+/HER2- Early Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribociclib (Primary) ; Antineoplastics; Gonadotropin releasing hormone
Indications Early breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms ADAPTcycle; WSG (West German Study Group)-ADAPTcycle

12 Nov 2024 Status changed from recruiting to active, no longer recruiting.
13 Sep 2022 Results assessing impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine therapy response, in ADAPT and its validation in the first part of ongoing phase III ADAPTcycle trial, presented at the 47th European Society for Medical Oncology Congress.
07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com